Alkermes plc (ALKS) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Alkermes plc Reports Second Quarter 2015 Financial Results
July 30, 2015 7:00 AM EDTSecond Quarter Revenues of $151.4 Million and Non-GAAP Diluted Loss Per Share of $0.09
Alkermes Unveils ARISTADA as Proposed Brand Name for Aripiprazole
Lauroxil;
Final Launch Preparations Underway in Advance of
Aug. 22, 2015 PDUFA Date
Company Improves Financial Expectations for 2015 Driven by Strong VIVITROL® Performance
DUBLIN--(BUSINESS WIRE)-- Alkermes plc... More
